ClinicalTrials.gg
RecruitingNCT07399977Updated Nov 9, 2026

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

An interventional study of MSK-ACCESS and ctDNA/VTE Risk Score: in Venous Thromboembolism and Deep Venous Thrombosis, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
259
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 221 studies in Venous Thromboembolism with a site in United States — 37 open to participants now, 40 under way, 8 of them phase 3. Venous Thromboembolism · United States.

Planned enrollment
80th of 165
259 · median 218
Started
2026
with 10 others
No phase
40 of 221
6 open now
Primary completion
2030-01
later than 33 of 39 live
Registered
213th of 221
by date

Among the 221 studies in Venous Thromboembolism with a site in United States, this one is the 80th largest by planned enrollment of the 165 interventional ones that give a count, is one of 11 that started in 2026, is one of 40 with no phase, reaches primary completion later than 33 of the 39 other live ones, and was the 213th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

37 of the 221 studies in Venous Thromboembolism with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 221 studies in Venous Thromboembolism with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.

03

Conditions studied

  • Venous Thromboembolism
  • Deep Venous Thrombosis

Keywords

  • Venous Thromboembolism
  • Deep Venous Thrombosis
  • 25-095
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental/unsuspected proximal lower-limb DVT, symptomatic pulmonary embolism [PE] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required).

Diagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.

Diagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.

  • Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):

    • breast cancer regardless of cytotoxic-chemotherapy status
    • hepatobiliary cancer regardless of cytotoxic-chemotherapy status
    • prostate cancer regardless of cytotoxic-chemotherapy status
    • non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days
    • pancreatic cancer with cytotoxic-chemotherapy received within 30 days
    • bladder cancer with cytotoxic-chemotherapy received within 30 days
  • Signed and dated by study participant/Legally Authorized Representative (LAR).

Exclusion criteria

Exclusion Criteria:

  • to ongoing anticoagulation
  • Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)
  • History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in levels of 1.24 mmol/L (2 g/dL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells).
  • Known diagnosis of disseminated intravascular coagulation (DIC)
  • Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE
  • Enrolled in hospice care
  • Currently has inferior vena cava (IVC) filter
  • Diagnosis of an active hematologic
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
259 participants (estimated)

Study arms

  • Experimental
    High risk for recurrent Venous Thromboembolism/VTE

    Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk.

    Diagnostic Test: MSK-ACCESS · Diagnostic Test: ctDNA/VTE Risk Score:

  • Experimental
    Low-risk for recurrent Venous Thromboembolism/VTE

    Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk.

    Diagnostic Test: MSK-ACCESS · Diagnostic Test: ctDNA/VTE Risk Score:

Interventions

  • Diagnostic testMSK-ACCESS

    MSK-ACCESS is a ctDNA sequencing assay

  • Diagnostic testctDNA/VTE Risk Score:

    Machine learning Venous Thromboembolism/VTE risk score mode

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of recurrent Venous Thromboembolism/VTE

    Evaluate the cumulative incidence of recurrent Venous Thromboembolism/VTE at 6 months following discontinuation of anticoagulation in participants with low risk DNA liquid biopsy-based model.

    Time frame: 6 months

07

Study locations

7 of 8 sites recruiting
  • Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Memorial Sloan Kettering Bergen (All Protocol Activities)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
    Commack, New York 11725, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Memorial Sloan Kettering Westchester (All Protocol Activities)
    Harrison, New York 10604, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)
    New York, New York 10065, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Memorial Sloan Kettering Nassau (All protocol activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Justin Jee, MD, PhD · Contact646-608-4409
  • Royal North Shore Hospital, Australia
    Sydney, 2065, Australia
    Not yet recruiting
    • Adrian Lee, MBBS, FRACP PhD · Contact02 8037 4100
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2030, 48 months after the start.

Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 48 months is above that.

Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Jan 30, 2026
Primary completionEst.
Jan 30, 2030
CompletionEst.
Jan 30, 2030
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07399977
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Jan 30, 2026
Primary completion
Jan 30, 2030 (estimated)
Completion
Jan 30, 2030 (estimated)
Last update
Nov 9, 2026

Study contacts

Justin Jee, MD, PhD
Contact
jeej@mskcc.org
646-608-4409
Jeffrey Zwicker, MD
Contact
zwickerj@mskcc.org
646-608-3723
Justine Jee, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion